Arbor Biotechnologies
Arbor Biotechnologies raises $215M Series C at $800M valuation
Quick Facts
Arbor Biotechnologies: Series C Funding Round
Arbor Biotechnologies has successfully raised $215M in Series C funding, reaching a valuation of $800M.
Company Overview
Gene editing technologies
Funding Details
The Series C round was led by Lightspeed Venture Partners, with participation from Redmile Group, Agent Capital, Amplitude Ventures.
Company Information
- Headquarters: 830 Winter Street, Waltham, MA 02451
- Founded: 2016
- Employees: 100+
- Category: Biotech
Investment
Arbor Biotechnologies plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Lightspeed Venture Partners: Verified investor in Series C
- Redmile Group: Verified investor in Series C
- Agent Capital: Verified investor in Series C
- Amplitude Ventures: Verified investor in Series C
Key Investors
About the Author

Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...

Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...

Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
